ALFA Finder| Revenue growth | 10% YoY in FY26. |
|---|---|
| Margins | EBITDA margins stable at ~45.5%; PAT margins compressing to 28.15%. |
| Demand visibility | Strong; Sanofi portfolio adds 13 established brands in 59 countries. |
| Management confidence | High; expanding technical capabilities into Peptides and Plasmids. |
Growth
FY26 revenue grew 10% YoY to INR 16,582 Lakhs; PAT declined 4% to INR 4,668 Lakhs.
Outlook
Targeting 990 KL capacity; forward integrating from intermediates to API and FDF; entering high-value Biologics and ADCs.
Risks
Integration of Japanese and European assets; dependency on anti-TB segment; regulatory approvals for pending acquisitions.
Earnings Call filed with BSE, NSE: GUJTHEM. Summary written with AI assistance from the document.
Gujarat Themis Biosyn Ltd: key numbers
- Share price
- ₹389.15
- Market cap
- ₹5,065 Cr
- Revenue (annual)
- ₹165.8 Cr
- Net profit (annual)
- ₹46.68 Cr
- P/E (TTM)
- 104.0×Sector 43.8×
- Promoter holding
- 59.33%-11.53% QoQ
- FII holding
- 3.80%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Themis Biosyn Ltd
All →Gujarat Themis Biosyn Preferential Issue
Gujarat Themis Biosyn clarified its preferential issue of up to 82,10,786 shares at Rs 408. The filing covers utilisation timelines, allottee beneficial owners and a PCS certificate.
- Value
- ₹3,350 Cr
Gujarat Themis Biosyn Board Meeting Date
Gujarat Themis Biosyn scheduled its board meeting for 4 Nov 2026 to approve Q2 and H2 un-audited results. No financial figures are disclosed in this advance intimation.
Gujarat Themis Biosyn Other Announcement
Gujarat Themis Biosyn clarified that its 9 October 2026 credit-rating intimation was uploaded in error and should be disregarded. No substantive business event is reported.
Gujarat Themis Biosyn Other Announcement
Gujarat Themis Biosyn Limited submitted the mandatory quarterly compliance certificate under SEBI Regulation 74(5) regarding dematerialization of shares for the quarter ended September 30, 2026.
Gujarat Themis Biosyn Annual General Meeting
Gujarat Themis Biosyn Ltd held its 45th Annual General Meeting on September 30, 2026, to deliberate on ordinary and special business resolutions.
Gujarat Themis Biosyn Annual General Meeting
Gujarat Themis Biosyn issued a corrigendum to its 45th AGM notice, updating the preferential issue resolution regarding share price, issue size, and allottee details.